Rotavirus vaccine, live, oral, tetravalent was licensed
On Aug. 31, 1998, Rotashield (Wyeth Laboratories, Marietta, Pennsylvania) was licensed by the U.S. Food and Drug Administration (FDA) for oral administration to infants at two, four and six months of age in the U.S. This product was a live, attenuated rhesus rotavirus based tetravalent vaccine (RRV-TV).
From September 1, 1998 to July 7, 1999, 15 cases of intussusception among infants who had received RRV-TV were reported to the Vaccine Adverse Event Reporting System.
Tags:
Source: U.S. National Library of Medicine
Credit: Image: Transmission electron microscopy (TEM) photo of rotavirus. Courtesy: Centers for Disease Control and Prevention.